| 查看: 413 | 回复: 1 | ||
| 本帖产生 1 个 翻译EPI ，点击这里进行查看 | ||
cainiaodui新虫 (小有名气)
|
[求助]
翻译求助
|
|
| Although Notch inhibitors are still preclinical, the monoclonal VEGF antibody bevacizumab is clinically available and represents a potential for combination therapy. As discussed above, some tumors are responsive to VEGF inhibition, although others are unresponsive and become resistant over time.This is most likely due to compensation by other angiogenic pathways that maintain the tumor vasculature. In patients with metastatic breast cancer, treatment with anti-VEGF therapy did not show a statistically significant increase in overall survival benefit.However, combination anti-angiogenic therapy may be useful in overcoming this resistance. |
回复此楼» 猜你喜欢
急需调剂
已经有3人回复
-
22408 312求调剂
已经有21人回复
-
恳请有学校收留
已经有4人回复
-
297，工科调剂?
已经有9人回复
-
300求调剂
已经有4人回复
-
291求调剂
已经有5人回复
-
085404 22408 309分求调剂
已经有10人回复
-
296求调剂
已经有13人回复
-
通信工程求调剂！！！
已经有6人回复
-
294求调剂
已经有7人回复
RXMCDM
版主 (文坛精英)
- 翻译EPI: 530
- 应助: 401 (硕士)
- 贵宾: 1.908
- 金币: 38947.6
- 散金: 4908
- 红花: 88
- 沙发: 4
- 帖子: 11453
- 在线: 1355.6小时
- 虫号: 2739168
- 注册: 2013-10-20
- 性别: GG
- 专业: 一般管理理论与研究方法论
- 管辖: 论文翻译
2楼2014-04-26 20:53:46
